Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Non-cash Items (2019 - 2022)

Nurix Therapeutics (NRIX) has disclosed Non-cash Items for 4 consecutive years, with $85.9 million as the latest value for Q3 2022.

  • On a quarterly basis, Non-cash Items rose 56.47% to $85.9 million in Q3 2022 year-over-year; TTM through Aug 2022 was $85.9 million, a 56.47% increase, with the full-year FY2021 number at $65.7 million, down 53.49% from a year prior.
  • Non-cash Items was $85.9 million for Q3 2022 at Nurix Therapeutics, up from $68.2 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $141.2 million in Q4 2020 to a low of $762000.0 in Q4 2019.
  • A 4-year average of $60.3 million and a median of $60.3 million in 2021 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: soared 18436.61% in 2020, then plummeted 53.49% in 2021.
  • Nurix Therapeutics' Non-cash Items stood at $762000.0 in 2019, then skyrocketed by 18436.61% to $141.2 million in 2020, then tumbled by 53.49% to $65.7 million in 2021, then surged by 30.76% to $85.9 million in 2022.
  • Per Business Quant, the three most recent readings for NRIX's Non-cash Items are $85.9 million (Q3 2022), $68.2 million (Q2 2022), and $75.2 million (Q1 2022).